The Influence of Resistant Flora on Costs and Their Structure During Pancreaticoduodenectomy

   Aim. Analysis of the economic costs of treating patients undergoing pancreaticoduodenectomy (PDE), depending on the resistance of the microflora in the bile.

   Materials and methods. This retrospective study included patients over the age of 18 who underwent PDE at the Moscow Clinical Scientific Center named after A. S. Loginov from January 2019 to May 2023. The patients were divided into two groups: patients without resistant strains in bile (group 1) and patients with resistant microflora (group 2). Subsequently, an assessment of the course of the postoperative period was carried out: the frequency of surgical site infections, the duration of hospitalization, the cost of diagnosis and treatment, as well as drug provision. The statistical analysis of the data was carried out using the R 3.4.2 statistical package.

   Results. The cost of laboratory diagnostics amounted to 41,895 rubles in group 1 and 56,180 rubles in group 2 (P = 0.21); 13,000 rubles for instrumental diagnostics in group 1 and 23,500 rubles in group 2 (P = 0.084); 1,500 rubles for antibacterial therapy in group 1 and 18,000 rubles in group 2 (P = 0.39); 76,011 rubles for concomitant therapy in group 1 and 113,012 rubles in group 2 (P = 0.013). Cost analysis in the groups revealed a significant difference — 157,407 rubles in group 1 versus 282,276 rubles in the group of patients with resistant flora (P = 0.1).

   Conclusion. The presence of resistant flora in patients undergoing PDE significantly increases treatment costs. The main cost-increasing factors are the high rate of infectious complications, the need to use reserve antibiotics, prolonged hospitalization, and prolonged concomitant therapy. The results highlight the importance of optimizing perioperative antibiotic prophylaxis in order to reduce costs and improve treatment effectiveness.

1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022 Feb 12; 399 (10325): 629–655. doi: 10.1016/S0140-6736 (21)02724-0.

2. Vertkin A. L., Prokhorovich E. A., Namazova L. S. Aleksanyan L. A., Shamuilova M. M. Optimization of empiric therapy for community-acquired pneumonia in elderly and senile patients. Russkiy Meditsinskiy Zhurnal = Russian Medical Journal. 2002; 16: 708–712. (in Russian)

3. Knorring G. Yu., Sternin Yu. I., Minaev S. V., Novozhilov A. A. Intensification of antibiotic therapy for pyoinflammatory diseases. Voenno-meditsinskii zhurnal. 2008; 329 (10): 35–41. (in Russian)

4. Griffin J. F., Poruk K. E., Wolfgang C. L. Pancreatic cancer surgery: past, present, and future. Chin J Cancer Res. 2015 Aug; 27 (4): 332–348. doi: 10.3978/j.issn.1000-9604.2015.06.07.

5. Cameron J. L., Riall T. S., Coleman J., Belcher K. A. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006 Jul; 244 (1): 10–15. doi: 10.1097/01.sla.0000217673.04165.ea.

6. Crist D. W., Sitzmann J. V., Cameron J. L. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg. 1987 Sep; 206 (3): 358–365. doi: 10.1097/00000658-198709000-00014.

7. Sohn T. A., Yeo C. J., Cameron J. L., Koniaris L., Kaushal S., Abrams R. A., Sauter P. K. et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000 Nov-Dec; 4 (6): 567–579. doi: 10.1016/s1091-255x (00)80105-5.

8. Amini N., Spolverato G., Kim Y., Pawlik T. M. Trends in Hospital Volume and Failure to Rescue for Pancreatic Surgery. J Gastrointest Surg. 2015 Sep; 19 (9): 1581–92. doi: 10.1007/s11605-015-2800-9.

9. Poruk K. E., Lin J. A., Cooper M. A., He J., Makary M. A., Hirose K. et al. A novel, validated risk score to predict surgical site infection after pancreaticoduodenectomy. HPB (Oxford). 2016 Nov; 18 (11): 893–899. doi: 10.1016/j.hpb.2016.07.011.

10. Morikane K. Epidemiology and risk factors associated with surgical site infection after different types of hepatobiliary and pancreatic surgery. Surg Today. 2017 Oct; 47 (10): 1208–1214. doi: 10.1007/s00595-017-1503-0.

11. Yang F., Jin C., Li J., Di Y., Zhang J., Fu D. Clinical significance of drain fluid culture after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci. 2018 Nov; 25 (11): 508–517. doi: 10.1002/jhbp.589.

12. Mintziras I., Maurer E., Kanngiesser V., Lohoff M., Bartsch D. K. Preoperative Bacterobilia Is an Independent Risk Factor of SSIs after Partial PD. Dig Surg. 2020; 37 (5): 428–435. doi: 10.1159/000508127.

13. Fathi A. H., Jackson T., Barati M., Eghbalieh B., Siegel K. A., Siegel C. T. Extended Perioperative Antibiotic Coverage in Conjunction with Intraoperative Bile Cultures Decreases Infectious Complications after Pancreaticoduodenectomy. HPB Surg. 2016; 2016: 3031749. doi: 10.1155/2016/3031749.

14. Bratzler D. W., Dellinger E. P., Olsen K. M., Perl T. M., Auwaerter P. G., Bolon M. K. et al.; American Society of Health-System Pharmacists; Infectious Disease Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013 Feb 1; 70 (3): 195–283. doi: 10.2146/ajhp120568.

15. Gomon Yu. M., Svetlichnaya Yu. S., Kolbin A. S., Sidorenko S. V., Daryina M. G., Zueva L. P., Kurylyov A. A., Ivanov I. G., Strizheletskiy V. V. Burden of resistant infections caused by S. aureus, E. coli, K. pneumoniae in Russian Federation. Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20 (4): 310–318. doi: 10.36488/cmac.2018.4.310-318. (in Russian)

16. Parshin D., S., Topchiev M. A., Astakhin V. A., Chechulina O. B., Smirnyagina E. O., Rayevsky E. N. Infections in the field of surgical intervention: risk factors for multiple antibiotic resistance in abdominal surgery. N. V. Sklifosovsky’s journal «Emergency Medical care». 2024 13 (3): 410–418. doi: 10.23934/2223-9022-2024-13-3-410-418. (in Russian)

17. Magiorakos A. P., Srinivasan A., Carey R. B., Carmeli Y., Falagas M. E., Giske C. G. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 Mar; 18 (3): 268–281. doi: 10.1111/j.1469-0691.2011.03570.x.

18. Idris F. N., Nadzir M. M. Multi-drug resistant ESKAPE pathogens and the uses of plants as their antimicrobial agents. Arch Microbiol. 2023 Mar 14; 205 (4): 115. doi: 10.1007/s00203-023-03455-6.

19. Yagudina R. I., Zinchuk I. Yu., Litvinenko M. M. The analysis of the «Cost of the disease»: types, methodology, features of implementation in the Russian Federation. Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2012; 5 (1): 4–9. (in Russian)

20. Cassini A., Plachouras D., Eckmanns T., Abu Sin M., Blank H. P., Ducomble T. et al. Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study. PLoS Med. 2016 Oct 18; 13 (10): e1002150. doi: 10.1371/journal.pmed.1002150.

21. Gasser M., Cassini A., Lo Fo Wong D., Gelormini M., Nahrgang S. A., Zingg W., Kronenberg A. O. Associated deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in Switzerland, 2010 to 2019. Euro Surveill. 2023 May; 28 (20): 2200532. doi: 10.2807/1560-7917.ES.2023.28.20.2200532.

22. Tacconelli E., Carrara E., Savoldi A., Harbarth S., Mendelson M., Monnet D. L. et al. WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar; 18 (3): 318–327. doi: 10.1016/S1473-3099 (17)30753-3.

23. Kim D., Park B. Y., Choi M. H., Yoon E. J., Lee H., Lee K. J. et al. Antimicrobial resistance and virulence factors of Klebsiella pneumoniae affecting 30 day mortality in patients with bloodstream infection. J Antimicrob Chemother. 2019 Jan 1; 74 (1): 190–199. doi: 10.1093/jac/dky397.

24. Giske C. G., Monnet D. L., Cars O., Carmeli Y.; ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008 Mar; 52 (3): 813–821. doi: 10.1128/AAC.01169-07.

25. Poudel A. N., Zhu S., Cooper N., Little P., Tarrant C., Hickman M., Yao G. The economic burden of antibiotic resistance : A systematic review and meta-analysis. PLoS One. 2023 May 8; 18 (5): e0285170. doi: 10.1371/journal.pone.0285170.

26. Tamma P. D., Aitken S. L., Bonomo R. A., Mathers A. J., van Duin D., Clancy C. J. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).Clin Infect Dis. 2021 Apr 8; 72 (7): 1109–1116. doi: 10.1093/cid/ciab295.

27. Baur D., Gladstone B. P., Burkert F., Carrara E., Foschi F., Döbele S., Tacconelli E. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection : a systematic review and meta-analysis. Lancet Infect Dis. 2017 Sep; 17 (9): 990–1001. doi: 10.1016/S1473-3099 (17)30325-0.